TDMS Study 92012-06 Pathology Tables
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 08/06/04
Route: DOSED FEED Time: 09:39:04
FINAL #1; REVISION #2 MICE
Facility: Southern Research Institute
Chemical CAS #: 693-98-1
Lock Date: 10/16/01
Cage Range: All
Reasons For Removal: 25019 Moribund Sacrifice 25020 Natural Death
25026 Other 25021 Terminal Sacrifice
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 08/06/04
Route: DOSED FEED Time: 09:39:04
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60 60
Early Deaths
Moribund Sacrifice 2 3 4 4
Natural Death 2 3 2 1
Survivors
Terminal Sacrifice 46 42 42 45
Moribund Sacrifice 1
Natural Death 1
Other 1 1
Animals Examined Microscopically 50 49 49 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (50) (48) (48) (50)
Edema 2 (4%) 2 (4%) 2 (4%)
Intestine Small, Jejunum (50) (46) (48) (49)
Hyperplasia, Lymphoid 1 (2%) 1 (2%)
Peyer's Patch, Infiltration Cellular,
Polymorphonuclear 1 (2%)
Intestine Small, Ileum (47) (49) (47) (48)
Hyperplasia, Lymphoid 1 (2%)
Peyer's Patch, Infiltration Cellular,
Polymorphonuclear 1 (2%)
Liver (50) (49) (49) (50)
Angiectasis 1 (2%)
Basophilic Focus 4 (8%) 1 (2%) 1 (2%)
Clear Cell Focus 1 (2%) 1 (2%) 4 (8%)
Eosinophilic Focus 1 (2%)
Hematopoietic Cell Proliferation 3 (6%) 3 (6%) 5 (10%) 3 (6%)
Hemorrhage 1 (2%)
Hepatodiaphragmatic Nodule 1 (2%) 2 (4%)
Hyperplasia, Lymphoid 3 (6%) 3 (6%) 6 (12%)
Infarct 1 (2%)
Infiltration Cellular, Mixed Cell 13 (26%) 5 (10%) 12 (24%) 10 (20%)
Mixed Cell Focus 4 (8%) 1 (2%) 3 (6%)
Necrosis, Focal 5 (10%) 2 (4%) 3 (6%) 4 (8%)
Tension Lipidosis 2 (4%)
Bile Duct, Hyperplasia 1 (2%)
Hepatocyte, Vacuolization Cytoplasmic 1 (2%)
Kupffer Cell, Pigmentation 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 08/06/04
Route: DOSED FEED Time: 09:39:04
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Mesentery (3) (4) (6) (6)
Inflammation, Chronic 1 (33%) 1 (25%)
Fat, Angiectasis 1 (17%) 1 (17%)
Fat, Necrosis 2 (67%) 3 (75%) 6 (100%) 6 (100%)
Pancreas (50) (49) (48) (50)
Atrophy 1 (2%)
Cyst 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Acinus, Cytoplasmic Alteration 2 (4%) 1 (2%)
Salivary Glands (50) (49) (49) (49)
Atrophy 2 (4%) 1 (2%)
Hyperplasia, Lymphoid 5 (10%) 3 (6%) 2 (4%)
Stomach, Forestomach (50) (49) (49) (50)
Diverticulum 1 (2%) 5 (10%)
Inflammation, Chronic Active 1 (2%) 1 (2%) 2 (4%)
Epithelium, Hyperplasia 1 (2%) 4 (8%) 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (49) (49) (50)
Cardiomyopathy 2 (4%)
Thrombosis 1 (2%)
Myocardium, Necrosis 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (49) (49) (50)
Accessory Adrenal Cortical Nodule 7 (14%) 5 (10%) 4 (8%) 6 (12%)
Hyperplasia, Focal 2 (4%)
Capsule, Hyperplasia 3 (6%)
Adrenal Medulla (50) (49) (49) (50)
Hyperplasia 1 (2%)
Islets, Pancreatic (50) (48) (48) (50)
Hyperplasia 1 (2%) 1 (2%) 1 (2%)
Parathyroid Gland (48) (46) (45) (48)
Cyst 1 (2%) 1 (2%) 1 (2%)
Pituitary Gland (50) (49) (47) (49)
Pars Distalis, Angiectasis 3 (6%) 1 (2%) 1 (2%)
Pars Distalis, Cyst 1 (2%) 3 (6%) 1 (2%)
Pars Distalis, Hyperplasia, Focal 1 (2%) 2 (4%) 1 (2%) 2 (4%)
Thyroid Gland (49) (48) (48) (50)
Degeneration, Cystic 15 (31%) 14 (29%) 12 (25%) 9 (18%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 08/06/04
Route: DOSED FEED Time: 09:39:04
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Follicle, Cyst 1 (2%) 1 (2%)
Follicular Cell, Hyperplasia 1 (2%) 1 (2%) 1 (2%) 9 (18%)
Follicular Cell, Hypertrophy 6 (12%) 3 (6%) 23 (48%) 46 (92%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (50) (48) (48) (50)
Inflammation, Chronic 1 (2%)
Ovary (50) (49) (49) (48)
Angiectasis 12 (24%) 7 (14%) 8 (16%) 8 (17%)
Cyst 10 (20%) 11 (22%) 15 (31%) 10 (21%)
Inflammation, Chronic 3 (6%) 2 (4%)
Thrombosis 1 (2%)
Corpus Luteum, Hyperplasia 1 (2%)
Uterus (50) (49) (49) (50)
Angiectasis 3 (6%) 2 (4%) 2 (4%) 6 (12%)
Inflammation, Chronic 6 (12%) 2 (4%) 9 (18%) 4 (8%)
Metaplasia, Squamous 5 (10%) 5 (10%) 1 (2%)
Cervix, Cyst Epithelial Inclusion 1 (2%)
Endometrium, Fibrosis 1 (2%)
Endometrium, Hyperplasia, Cystic 48 (96%) 47 (96%) 46 (94%) 45 (90%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (49) (48) (50)
Hyperplasia 10 (20%) 5 (10%) 13 (27%) 16 (32%)
Lymph Node (12) (6) (8) (9)
Bronchial, Hyperplasia, Lymphoid 1 (8%) 2 (22%)
Iliac, Ectasia 1 (13%)
Iliac, Hematopoietic Cell Proliferation 2 (17%) 1 (17%) 1 (13%)
Iliac, Hyperplasia, Lymphoid 5 (42%) 3 (50%) 4 (50%) 2 (22%)
Iliac, Pigmentation 1 (17%)
Inguinal, Hyperplasia, Lymphoid 1 (13%)
Lumbar, Hyperplasia, Lymphoid 1 (8%) 1 (17%) 2 (25%) 2 (22%)
Lumbar, Pigmentation 1 (17%)
Mediastinal, Hyperplasia, Lymphoid 1 (8%) 1 (17%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 08/06/04
Route: DOSED FEED Time: 09:39:04
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Pancreatic, Hyperplasia, Lymphoid 1 (13%)
Renal, Hematopoietic Cell Proliferation 1 (8%) 1 (13%)
Renal, Hyperplasia, Lymphoid 3 (25%) 1 (17%) 2 (25%)
Lymph Node, Mandibular (48) (48) (46) (48)
Atrophy 2 (4%)
Hematopoietic Cell Proliferation 3 (6%)
Hemorrhage 1 (2%)
Hyperplasia, Lymphoid 11 (23%) 12 (25%) 10 (22%) 15 (31%)
Hyperplasia, Plasma Cell 2 (4%) 1 (2%) 4 (9%)
Pigmentation 24 (50%) 20 (42%) 21 (46%) 21 (44%)
Lymph Node, Mesenteric (48) (48) (47) (48)
Ectasia 1 (2%)
Hematopoietic Cell Proliferation 5 (10%) 3 (6%) 3 (6%)
Hemorrhage 1 (2%) 1 (2%)
Hyperplasia, Lymphoid 3 (6%) 7 (15%) 4 (9%) 6 (13%)
Hyperplasia, Plasma Cell 1 (2%)
Spleen (50) (49) (49) (50)
Angiectasis 1 (2%)
Atrophy 1 (2%) 1 (2%)
Congestion 2 (4%)
Hematopoietic Cell Proliferation 15 (30%) 20 (41%) 24 (49%) 39 (78%)
Hyperplasia, Plasma Cell 1 (2%)
Pigmentation 4 (8%) 11 (22%) 34 (68%)
Lymphoid Follicle, Atrophy 1 (2%) 3 (6%) 5 (10%) 4 (8%)
Lymphoid Follicle, Hyperplasia 12 (24%) 14 (29%) 13 (27%) 16 (32%)
Thymus (50) (48) (48) (50)
Atrophy 5 (10%) 2 (4%) 7 (15%) 3 (6%)
Hyperplasia, Lymphoid 4 (8%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (49) (49) (50)
Hyperplasia 2 (4%) 2 (4%)
Skin (50) (49) (49) (50)
Edema 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (49) (49) (50)
Hyperostosis 9 (18%) 13 (27%) 10 (20%) 11 (22%)
Skeletal Muscle (1) (1)
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 08/06/04
Route: DOSED FEED Time: 09:39:04
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM - CONT
Necrosis 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (49) (49) (50)
Hemorrhage 1 (2%) 1 (2%)
Inflammation, Chronic Active 1 (2%)
Vacuolization Cytoplasmic 1 (2%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (49) (49) (50)
Edema 2 (4%) 1 (2%)
Foreign Body 2 (4%) 2 (4%) 2 (4%)
Hemorrhage 4 (8%) 3 (6%) 1 (2%) 4 (8%)
Hyperplasia, Lymphoid 9 (18%) 6 (12%) 3 (6%) 7 (14%)
Infiltration Cellular, Histiocyte 2 (4%) 2 (4%) 3 (6%)
Thrombosis 1 (2%) 1 (2%)
Alveolar Epithelium, Hyperplasia 1 (2%) 2 (4%) 3 (6%) 2 (4%)
Nose (50) (49) (49) (50)
Foreign Body 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (50) (49) (49) (50)
Atrophy 1 (2%)
Cataract 1 (2%) 2 (4%)
Inflammation, Chronic 1 (2%) 2 (4%)
Harderian Gland (50) (49) (49) (50)
Hyperplasia 1 (2%)
Hyperplasia, Focal 3 (6%) 2 (4%) 1 (2%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (49) (49) (50)
Cyst 1 (2%) 2 (4%) 1 (2%) 1 (2%)
Hyperplasia, Lymphoid 8 (16%) 16 (33%) 8 (16%) 4 (8%)
Infarct 2 (4%) 2 (4%)
Inflammation, Chronic 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 08/06/04
Route: DOSED FEED Time: 09:39:04
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Metaplasia, Osseous 1 (2%) 2 (4%)
Nephropathy 27 (54%) 17 (35%) 21 (43%) 19 (38%)
Papilla, Necrosis 1 (2%)
Renal Tubule, Accumulation, Hyaline Droplet 1 (2%) 1 (2%)
Renal Tubule, Dilatation 1 (2%)
Renal Tubule, Necrosis 1 (2%) 1 (2%)
Renal Tubule, Pigmentation 2 (4%)
Urinary Bladder (50) (49) (49) (50)
Hyperplasia, Lymphoid 16 (32%) 16 (33%) 6 (12%) 11 (22%)
Inflammation, Chronic 1 (2%) 1 (2%)
Transitional Epithelium, Hyperplasia 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 08/06/04
Route: DOSED FEED Time: 09:39:04
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60 60
Early Deaths
Moribund Sacrifice 4 1 5 5
Natural Death 3 3 9 5
Survivors
Terminal Sacrifice 43 46 36 40
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Large, Cecum (49) (49) (47) (50)
Edema 2 (4%) 1 (2%) 1 (2%) 1 (2%)
Intestine Small, Duodenum (49) (49) (45) (50)
Epithelium, Hyperplasia 1 (2%)
Intestine Small, Jejunum (50) (49) (46) (50)
Hyperplasia, Lymphoid 1 (2%) 1 (2%)
Infiltration Cellular, Polymorphonuclear 1 (2%)
Intestine Small, Ileum (49) (50) (45) (49)
Hyperplasia, Lymphoid 1 (2%) 1 (2%)
Infiltration Cellular, Polymorphonuclear 1 (2%)
Liver (50) (50) (50) (50)
Angiectasis 2 (4%) 1 (2%)
Basophilic Focus 2 (4%) 3 (6%) 1 (2%) 3 (6%)
Clear Cell Focus 6 (12%) 9 (18%) 6 (12%) 8 (16%)
Cyst 1 (2%)
Eosinophilic Focus 3 (6%) 3 (6%) 2 (4%) 6 (12%)
Hematopoietic Cell Proliferation 1 (2%) 2 (4%) 2 (4%)
Hepatodiaphragmatic Nodule 1 (2%)
Infarct 1 (2%)
Infiltration Cellular, Mixed Cell 5 (10%) 7 (14%) 7 (14%) 7 (14%)
Mixed Cell Focus 4 (8%) 3 (6%) 4 (8%) 4 (8%)
Necrosis, Diffuse 1 (2%)
Necrosis, Focal 2 (4%) 6 (12%) 2 (4%) 6 (12%)
Tension Lipidosis 2 (4%) 1 (2%)
Hepatocyte, Cytoplasmic Alteration 11 (22%) 37 (74%)
Hepatocyte, Karyomegaly 10 (20%) 29 (58%)
Hepatocyte, Vacuolization Cytoplasmic 1 (2%) 1 (2%)
Kupffer Cell, Pigmentation 1 (2%) 1 (2%) 19 (38%)
Mesentery (6) (2) (5) (2)
Angiectasis 1 (50%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 08/06/04
Route: DOSED FEED Time: 09:39:04
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Inflammation, Chronic 1 (50%)
Fat, Necrosis 4 (67%) 1 (50%) 3 (60%) 2 (100%)
Pancreas (50) (50) (49) (50)
Atrophy 1 (2%) 1 (2%)
Cyst 2 (4%) 3 (6%) 2 (4%)
Acinus, Cytoplasmic Alteration 2 (4%) 1 (2%)
Salivary Glands (50) (50) (50) (50)
Hyperplasia, Lymphoid 2 (4%) 2 (4%)
Stomach, Forestomach (50) (49) (50) (50)
Diverticulum 2 (4%)
Inflammation, Chronic Active 1 (2%) 1 (2%)
Ulcer 1 (2%) 1 (2%)
Epithelium, Hyperplasia 2 (4%) 2 (4%) 1 (2%) 1 (2%)
Stomach, Glandular (50) (49) (49) (50)
Glands, Dysplasia 1 (2%)
Tooth (1)
Inflammation, Chronic 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (50) (50)
Cardiomyopathy 1 (2%) 1 (2%)
Perivascular, Inflammation, Chronic 3 (6%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (50) (50)
Accessory Adrenal Cortical Nodule 2 (4%) 6 (12%) 8 (16%) 6 (12%)
Hyperplasia, Focal 2 (4%) 4 (8%) 3 (6%) 1 (2%)
Hypertrophy, Focal 13 (26%) 18 (36%) 10 (20%) 10 (20%)
Capsule, Hyperplasia 1 (2%) 2 (4%) 3 (6%) 2 (4%)
Adrenal Medulla (50) (50) (50) (50)
Hyperplasia 2 (4%)
Islets, Pancreatic (50) (50) (49) (50)
Hyperplasia 2 (4%) 1 (2%)
Parathyroid Gland (49) (47) (45) (48)
Cyst 3 (6%) 1 (2%) 2 (4%) 1 (2%)
Pituitary Gland (49) (48) (48) (50)
Pars Distalis, Cyst 2 (4%) 1 (2%) 2 (4%) 2 (4%)
Pars Distalis, Hyperplasia, Focal 1 (2%)
Thyroid Gland (50) (50) (50) (50)
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 08/06/04
Route: DOSED FEED Time: 09:39:04
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Degeneration, Cystic 10 (20%) 2 (4%) 3 (6%) 4 (8%)
Follicular Cell, Hyperplasia 2 (4%) 3 (6%) 33 (66%)
Follicular Cell, Hypertrophy 1 (2%) 6 (12%) 25 (50%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (50) (50)
Fibrosis 1 (2%)
Granuloma Sperm 3 (6%) 6 (12%)
Hyperplasia, Lymphoid 2 (4%) 1 (2%)
Hypospermia 1 (2%)
Inflammation, Chronic Active 1 (2%) 3 (6%) 7 (14%) 8 (16%)
Penis (1) (1) (1)
Angiectasis 1 (100%) 1 (100%)
Preputial Gland (50) (50) (50) (50)
Cyst 18 (36%) 23 (46%) 16 (32%) 21 (42%)
Inflammation, Chronic 14 (28%) 10 (20%) 14 (28%) 7 (14%)
Prostate (49) (50) (49) (50)
Inflammation, Chronic 2 (4%)
Seminal Vesicle (50) (50) (50) (50)
Atrophy 1 (2%)
Testes (50) (50) (50) (50)
Germinal Epithelium, Atrophy 1 (2%) 4 (8%) 8 (16%) 14 (28%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (50) (50)
Hyperplasia 4 (8%) 10 (20%) 20 (40%) 42 (84%)
Lymph Node (2) (3) (1)
Bronchial, Hyperplasia, Lymphoid 1 (33%)
Lymph Node, Mandibular (48) (46) (45) (50)
Atrophy 1 (2%) 2 (4%) 4 (8%)
Ectasia 1 (2%)
Hyperplasia, Lymphoid 10 (21%) 14 (30%) 9 (20%) 13 (26%)
Pigmentation 8 (17%) 6 (13%) 9 (20%) 6 (12%)
Lymph Node, Mesenteric (47) (47) (46) (48)
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 08/06/04
Route: DOSED FEED Time: 09:39:04
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Angiectasis 1 (2%)
Atrophy 1 (2%) 1 (2%) 2 (4%) 2 (4%)
Hemorrhage 4 (9%) 2 (4%) 2 (4%)
Hyperplasia, Lymphoid 7 (15%) 7 (15%) 15 (33%) 10 (21%)
Necrosis 1 (2%) 1 (2%)
Spleen (50) (50) (49) (50)
Angiectasis 1 (2%)
Atrophy 1 (2%) 4 (8%) 3 (6%)
Hematopoietic Cell Proliferation 10 (20%) 21 (42%) 38 (78%) 45 (90%)
Pigmentation 1 (2%) 16 (32%) 33 (67%) 43 (86%)
Lymphoid Follicle, Atrophy 4 (8%) 14 (29%) 30 (60%)
Lymphoid Follicle, Hyperplasia 5 (10%) 2 (4%) 2 (4%)
Thymus (47) (46) (46) (47)
Atrophy 7 (15%) 5 (11%) 9 (20%) 8 (17%)
Cyst 1 (2%) 1 (2%) 1 (2%)
Hyperplasia, Lymphoid 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (50) (50)
Inflammation, Chronic 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (1) (1) (2)
Atrophy 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (50) (50)
Compression 1 (2%)
Peripheral Nerve (1) (1)
Atrophy 1 (100%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (50) (50) (50) (50)
Edema 1 (2%) 3 (6%) 1 (2%) 3 (6%)
Hemorrhage 4 (8%) 8 (16%) 4 (8%) 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 11
NTP Experiment-Test: 92012-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 2-METHYLIMIDAZOLE Date: 08/06/04
Route: DOSED FEED Time: 09:39:04
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 625 PPM 1250 PPM 2500 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - CONT
Hyperplasia, Lymphoid 1 (2%) 2 (4%) 2 (4%) 4 (8%)
Infiltration Cellular, Histiocyte 4 (8%) 4 (8%) 4 (8%) 2 (4%)
Inflammation, Chronic 1 (2%) 2 (4%)
Metaplasia, Osseous 2 (4%)
Thrombosis 1 (2%) 1 (2%)
Alveolar Epithelium, Hyperplasia 5 (10%) 3 (6%) 1 (2%) 3 (6%)
Alveolar Epithelium, Hyperplasia, Multifocal 1 (2%)
Nose (50) (50) (50) (50)
Foreign Body 1 (2%) 3 (6%) 3 (6%) 2 (4%)
Inflammation, Chronic 1 (2%) 4 (8%) 3 (6%) 2 (4%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (50) (50) (50) (50)
Cataract 1 (2%) 1 (2%)
Inflammation, Chronic 1 (2%) 2 (4%) 2 (4%) 2 (4%)
Cornea, Hyperplasia 1 (2%) 1 (2%)
Harderian Gland (50) (50) (48) (50)
Hyperplasia, Focal 1 (2%) 2 (4%)
Inflammation, Chronic 3 (6%) 4 (8%) 2 (4%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (50) (50)
Cyst 13 (26%) 11 (22%) 12 (24%) 19 (38%)
Hydronephrosis 1 (2%)
Hyperplasia, Lymphoid 1 (2%) 3 (6%) 3 (6%) 3 (6%)
Infarct 6 (12%) 6 (12%) 6 (12%) 1 (2%)
Inflammation, Suppurative 1 (2%)
Metaplasia, Osseous 5 (10%) 3 (6%) 2 (4%) 3 (6%)
Nephropathy 34 (68%) 43 (86%) 32 (64%) 31 (62%)
Papilla, Necrosis 1 (2%)
Renal Tubule, Hyperplasia 1 (2%) 1 (2%) 2 (4%) 3 (6%)
Renal Tubule, Pigmentation 1 (2%) 2 (4%) 45 (90%)
Urethra (1)
Angiectasis 1 (100%)
Inflammation, Suppurative 1 (100%)
Urinary Bladder (50) (50) (50) (50)
Transitional Epithelium, Hyperplasia 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 12
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------